Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EBV-AST cell

Phase 2Biologic

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ViremiaRecruiting

EBV-Associated Lymphoproliferative DisordersRecruiting

ViremiaPhase 1

Recruiting

EBV-Associated Lymphoproliferative DisordersPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

EBV-Associated Lymphoproliferative Disorders

NCT07450391

Q1 2028

Phase 1Recruiting

Viremia

NCT07438067

Clinical

Trials by Indication[1]

EBV-Associated Lymphoproliferative Disorders1 trial

EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

Recruiting·DDaihong Liu·Phase 1/2·NCT07450391·18 enrolled

Viremia1 trial

A Prospective Exploratory Study of EBV-AST Cell Injection for the Treatment of EBV-Related Diseases After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·DDaihong Liu·Phase 1·NCT07438067·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EBV-AST cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EBV-AST cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EBV-AST cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daihong Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: DDaihong Liu

Related News